WO2003002514A1 - 3-aryl-alpha-amino propanoic acid derivatives and a process for their preparation - Google Patents

3-aryl-alpha-amino propanoic acid derivatives and a process for their preparation Download PDF

Info

Publication number
WO2003002514A1
WO2003002514A1 PCT/IN2001/000126 IN0100126W WO03002514A1 WO 2003002514 A1 WO2003002514 A1 WO 2003002514A1 IN 0100126 W IN0100126 W IN 0100126W WO 03002514 A1 WO03002514 A1 WO 03002514A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
carried out
protecting group
amino
Prior art date
Application number
PCT/IN2001/000126
Other languages
French (fr)
Inventor
Om Reddy Gaddam
Ramabhadra Sarma Mamillapalli
Chandrasekhar Batchu
Satyanarayana Vara Prasad Reddy Tetali
Original Assignee
Dr. Reddy's Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Research Foundation filed Critical Dr. Reddy's Research Foundation
Priority to PCT/IN2001/000126 priority Critical patent/WO2003002514A1/en
Publication of WO2003002514A1 publication Critical patent/WO2003002514A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to novel antidiabetic compounds, their derivatives, their analogs and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel 3- aryl propanoic acid of the general formula (I), their derivatives, their analogs and pharmaceutically acceptable compositions containing them
  • R represents hydroxy or a protecting group such as (C]-C 8 )alkoxy- CH 2 -O-, mesylate, tosylate, triflate or halogen atom such as fluorine, chlorine, bromine or iodine.
  • the present invention also relates to a process for the preparation of compounds of formula (I).
  • the present invention also relates to novel intermediates of formula
  • the compounds of formula (I) are useful in lowering the plasma glucose, triglyceride, total cholesterol (TC); increase high density lipoprotein (HDL) and decrease low density lipoprotein (LDL).
  • the compounds of formula (I) are useful in reducing body weight, glucose intolerance and for the treatment and / or prophylaxis of diseases such as hypertension, coronary heart disease, atherosclerosis, stroke, peripheral vascular diseases and related disorders.
  • the compound of formula (I) is also useful for the treatment and/or prophylaxis of insulin resistance (type II diabetes).
  • the compounds of formula (I) are useful as intermediates for the preparation of many pharmaceutically active compounds. Few representative examples of such compounds are disclosed in WO 99/62870 and
  • WO 96/01901 describes the streptogramines and method for preparing the same by muta synthesis, in which they have disclosed L-Tyrosine, O-(2- chloroethyl)-, hydrochloride.
  • WO 99/66870 and WO 99/66872 describes compounds of formula (lie)
  • A is chiral auxiliary group, -OH or OR p , wherein R p is a protective group, example ethyl, Q is hydrogen, -CH 2 -CH 2 Ph-4-OSO 2 CH 3 or R q , wherein R q is a protective group, example benzyl.
  • W 1 represents is alkylene
  • W 2 represents single bond or alkylene
  • n represents alkylene
  • the main objective of the present invention is to provide novel compounds of the formula (I) for the treatment and / or prophylaxis of diabetes with high chiral purity, which can be used in the synthesis of pharmaceutically acceptable compounds, which will not have problems of racemization in subsequent steps, when used in the preparation of pharmaceutically acceptable compounds.
  • Another objective of the present invention is to provide a simple and robust process for the preparation of the compound of formula (I).
  • the present invention relates to novel 3-aryl propanoic acid derivatives of the formula (I) wherein R represents hydroxy or a protecting group such as (CrC 8 )alkoxy- CH 2 -O-, mesylate, tosylate, triflate or halogen atom such as fluorine, chlorine, bromine or iodine.
  • R represents hydroxy or a protecting group such as (CrC 8 )alkoxy- CH 2 -O-, mesylate, tosylate, triflate or halogen atom such as fluorine, chlorine, bromine or iodine.
  • Particularly useful compounds of the formula (I) according to the present invention include :
  • R represents hydroxy or a protecting group such as (C C 8 )alkoxy-CH 2 - O-, mesylate, tosylate, triflate or halogen atom, which comprises : i). protecting L-tyrosine of the formula (III) with protecting groups such as copper acetate, acetone, benzaldehyde in the presence of a base to produce a compound of formula (IV) where X represents a protecting group such as copper, acetonide, benzylidine and the like, ii). reacting the compound of formula (IV) with compound of formula (V) where R is as defined above and L 1 is a leaving group such as halogen, hydroxy, mesylate, tosylate and the like to produce a compound of formula
  • reaction of compound of formula (III) with protecting group such as copper acetate, acetone, benzaldehyde to produce compound of formula (IV) may be carried in the presence of alkaline solutions such as sodium carbonate, potassium carbonate, NaH, NaOMe, potassium tertiary butoxide and the like.
  • alkaline solutions such as sodium carbonate, potassium carbonate, NaH, NaOMe, potassium tertiary butoxide and the like.
  • the reaction may be carried out at a temperature in the range of 40 C to 140 °C, for a period in the range of 2 h to 20 h.
  • reaction of compound of the formula (IV) with mesylate of the formula (V) where R is as defined above may be carried out in the presence of bases such as potassium carbonate, sodium carbonate and the like.
  • bases such as potassium carbonate, sodium carbonate and the like.
  • the reaction may also be carried out in the presence of solvents such as toluene, xylene, DMF, DMA and the like.
  • the reaction may be carried out at temperature in the range of 60 to 110 °C and the duration of the reaction may range from 2-40 h.
  • the deprotection of compound of formula (VI) to produce compound of the formula (I) where R is as defined above may be carried out in the presence of acids such as hydrochloric acid, sulfuric acid, acetic acid and the like.
  • the reaction may be carried out in the presence of solvents such as methanol, ethanol, propanol, isopropanol and the like.
  • the reaction may be carried out at a temperature in the range of 60 to 110 °C and the duration of the reaction may range from 2-40 h.
  • X is a protecting group such as copper, acetonide, benzylidine and the like.
  • R represents hydroxy or a protecting group such as (Cj-C 8 )alkoxy- CH 2 -O-, mesylate, tosylate, triflate or halogen atom such as fluorine, chlorine, bromine or iodine;
  • X is a protecting group such as copper, acetonide, benzylidine and the like.
  • any reactive group in the substrate molecule may be protected according to conventional chemical practice.
  • Suitable protecting groups in any of the above mentioned reactions are tertiarybutyl dimethyl silylchloride, methoxymethyl chloride and the like. The methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected.
  • mice C57 BL/KsJ-db/db mice developed by Jackson Laboratory, US, are obese, hyperglycemic, hyperinsulinemic and insulin resistant (J. Clin. Invest., (1990) 85 : 962-967), whereas heterozygous are lean and normoglycemic.
  • db/db model mouse progressively develops insulinopenia with age, a feature commonly observed in late stages of human type II diabetes when blood sugar levels are insufficiently controlled.
  • the state of pancreas and its course vary according to the models. Since this model resembles that of type II diabetes mellitus, the compounds of the present invention were tested for blood sugar and triglycerides lowering activities.
  • mice of 8 to 14 weeks age having body weight range of 35 to 60 grams, bred at Dr. Reddy's Research Foundation (DRF) animal house, were used in the experiment.
  • the mice were provided with standard feed (National Institute of Nutrition (NTN), India) and acidified water, ad libitum.
  • NTN National Institute of Nutrition
  • The. animals having more than 350 mg / dl blood sugar were used for testing.
  • the number of animals in each group was 4.
  • Test compounds were suspended on 0.25 % carboxymethyl cellulose and administered to test group at a dose of 0.1 mg to 30 mg / kg through oral gavage daily for 6 days.
  • the control group received vehicle (dose 10 ml / kg).
  • the blood samples were collected one hour after administration of test compounds / vehicle for assessing the biological activity.
  • the random blood sugar and triglyceride levels were measured by collecting blood (100 ⁇ l) through orbital sinus, using heparinised capillary in tubes containing EDTA which was centrifuged to obtain plasma.
  • the plasma glucose and triglyceride levels were measured spectrometrically, by glucose oxidase and glycerol-3-PO 4 oxidase/peroxidase enzyme (Dr. Reddy's Lab. Diagnostic Division Kits, India) methods respectively.
  • the blood sugar and triglycerides lowering activities of the test compound was calculated according to the formula.
  • Percent reduction in Blood sugar can be calculated according to the formula :

Abstract

The present invention relates to novel antidiabetic compounds, their derivatives, their analogs and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel 3-aryl propanoic acid of the general formula (I), their derivatives, their analogs and pharmaceutically acceptable compositions containing them wherein R represents hydroxy or a protecting group such as (C1-C8)alkoxy-CH2-O-, mesylate, tosylate, triflate or halogen atom such as fluorine, chlorine, bromine or iodine.

Description

3-ARYL-α-AMINO PROPANOIC DERIVATIVES AND PROCESS FOR THEIR
PREPARATION
Field of the invention
The present invention relates to novel antidiabetic compounds, their derivatives, their analogs and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel 3- aryl propanoic acid of the general formula (I), their derivatives, their analogs and pharmaceutically acceptable compositions containing them
Figure imgf000002_0001
wherein R represents hydroxy or a protecting group such as (C]-C8)alkoxy- CH2-O-, mesylate, tosylate, triflate or halogen atom such as fluorine, chlorine, bromine or iodine.
The present invention also relates to a process for the preparation of compounds of formula (I). The present invention also relates to novel intermediates of formula
(IV) and (VI) and their use in the preparation of compounds of formula (I).
The compounds of formula (I) are useful in lowering the plasma glucose, triglyceride, total cholesterol (TC); increase high density lipoprotein (HDL) and decrease low density lipoprotein (LDL). The compounds of formula (I) are useful in reducing body weight, glucose intolerance and for the treatment and / or prophylaxis of diseases such as hypertension, coronary heart disease, atherosclerosis, stroke, peripheral vascular diseases and related disorders. The compound of formula (I) is also useful for the treatment and/or prophylaxis of insulin resistance (type II diabetes).
The compounds of formula (I) are useful as intermediates for the preparation of many pharmaceutically active compounds. Few representative examples of such compounds are
Figure imgf000003_0001
disclosed in WO 99/62870 and
Figure imgf000003_0002
disclosed in WO 99/16758. The compounds of formulae (Ila) and (lib) are shown to have potent blood glucose lowering, triglyceride lowering, cholesterol lowering and body weight reducing activities.
Background of invention
WO 96/01901 describes the streptogramines and method for preparing the same by muta synthesis, in which they have disclosed L-Tyrosine, O-(2- chloroethyl)-, hydrochloride.
WO 99/66870 and WO 99/66872 describes compounds of formula (lie)
Figure imgf000003_0003
where A is chiral auxiliary group, -OH or ORp, wherein Rp is a protective group, example ethyl, Q is hydrogen, -CH2-CH2Ph-4-OSO2CH3 or Rq, wherein Rq is a protective group, example benzyl.
WO 00/59889 describes compounds of formula (lid) as an intermediate
Figure imgf000003_0004
wherein W1 represents is alkylene, W2 represents single bond or alkylene, and n
B represents O or S, R represents -hydrogen or the like, for preparing the compounds of formula (He)
Figure imgf000004_0001
The process for preparing compounds of formula (lid) comprises reacting the compound of formula (Ilf) with MsCl, NaN3 and then followed by reduction is shown in scheme 1 below :
Figure imgf000004_0002
Scheme-1
Objective of present invention
The main objective of the present invention is to provide novel compounds of the formula (I) for the treatment and / or prophylaxis of diabetes with high chiral purity, which can be used in the synthesis of pharmaceutically acceptable compounds, which will not have problems of racemization in subsequent steps, when used in the preparation of pharmaceutically acceptable compounds.
Another objective of the present invention is to provide a simple and robust process for the preparation of the compound of formula (I).
Detailed description of the invention
Accordingly, the present invention relates to novel 3-aryl propanoic acid derivatives of the formula (I)
Figure imgf000005_0001
wherein R represents hydroxy or a protecting group such as (CrC8)alkoxy- CH2-O-, mesylate, tosylate, triflate or halogen atom such as fluorine, chlorine, bromine or iodine.
Particularly useful compounds of the formula (I) according to the present invention, include :
(-) 2-Amino 3-[4-(2-chloroethoxy)phenyl]propanoic acid ; (-) 2-Amino 3-[4-(2-bromoethoxy)phenyl]propanoic acid ; (-) 2-Amino 3-[4-(2-methoxymethoxyethoxy)phenyl]propanoic acid ; (-) 2-Amino 3-[4-(2-ethoxymethoxyethoxy)phenyl]propanoic acid ; (-) 2-Amino 3-[4-[2-(4-methylphenyl sulfonyloxy)ethoxy]phenyl]propanoic acid ;
According to another embodiment of the present invention there is provided a process for the preparation of novel 3-aryl propanoic acid derivatives of the formula (I)
Figure imgf000005_0002
where R represents hydroxy or a protecting group such as (C C8)alkoxy-CH2- O-, mesylate, tosylate, triflate or halogen atom, which comprises : i). protecting L-tyrosine of the formula (III) with protecting groups such as copper acetate, acetone, benzaldehyde in the presence of a base to produce a compound of formula (IV) where X represents a protecting group such as copper, acetonide, benzylidine and the like, ii). reacting the compound of formula (IV) with compound of formula (V) where R is as defined above and L1 is a leaving group such as halogen, hydroxy, mesylate, tosylate and the like to produce a compound of formula
(VI) iii). deprotecting the compound of formula (VI) to yield pure compound of formula (I).
The process explained above is shown in scheme-2 below :
Figure imgf000006_0001
Scheme-2
The reaction of compound of formula (III) with protecting group such as copper acetate, acetone, benzaldehyde to produce compound of formula (IV) may be carried in the presence of alkaline solutions such as sodium carbonate, potassium carbonate, NaH, NaOMe, potassium tertiary butoxide and the like. The reaction may be carried out at a temperature in the range of 40 C to 140 °C, for a period in the range of 2 h to 20 h.
The reaction of compound of the formula (IV) with mesylate of the formula (V) where R is as defined above may be carried out in the presence of bases such as potassium carbonate, sodium carbonate and the like. The reaction may also be carried out in the presence of solvents such as toluene, xylene, DMF, DMA and the like. The reaction may be carried out at temperature in the range of 60 to 110 °C and the duration of the reaction may range from 2-40 h.
The deprotection of compound of formula (VI) to produce compound of the formula (I) where R is as defined above may be carried out in the presence of acids such as hydrochloric acid, sulfuric acid, acetic acid and the like. The reaction may be carried out in the presence of solvents such as methanol, ethanol, propanol, isopropanol and the like. The reaction may be carried out at a temperature in the range of 60 to 110 °C and the duration of the reaction may range from 2-40 h.
According to another embodiment of the present invention there is provided a novel intermediate of formula (IV)
Figure imgf000007_0001
wherein X is a protecting group such as copper, acetonide, benzylidine and the like.
According to yet another embodiment of the present invention there is provided a novel intermediate of formula (VI)
Figure imgf000007_0002
wherein R represents hydroxy or a protecting group such as (Cj-C8)alkoxy- CH2-O-, mesylate, tosylate, triflate or halogen atom such as fluorine, chlorine, bromine or iodine; X is a protecting group such as copper, acetonide, benzylidine and the like. The compounds of formula (I) are useful in the preparation of pharmaceutically important compounds such as
Figure imgf000008_0001
The process for preparing the compounds of formula (lib) starting from compound of formula (I) is as shown in scheme -3 :
Figure imgf000008_0002
(lib) (lie)
Scheme - 3
It is appreciated that in any 'of the above mentioned reactions, any reactive group in the substrate molecule may be protected according to conventional chemical practice. Suitable protecting groups in any of the above mentioned reactions are tertiarybutyl dimethyl silylchloride, methoxymethyl chloride and the like. The methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected.
Demonstration of Efficacy of Compounds Efficacy in genetic models Mutation in colonies of laboratory animals and different sensitivities to dietary regimens have made the development of animal models with non- insulin dependent diabetes and ' hyperlipidemia associated with obesity and insulin resistance possible. Genetic models such as db/db and ob/ob (Diabetes, (1982) 31(1) : 1- 6) mice and zucker fa/fa rats have been developed by the various laboratories for understanding the pathophysiology of disease and testing the efficacy of new antidiabetic compounds (Diabetes, (1983) 32: 830-838 ; A nu. Rep. Sankyo Res. Lab. (1994). 46 : 1-57). The homozygous animals, C57 BL/KsJ-db/db mice developed by Jackson Laboratory, US, are obese, hyperglycemic, hyperinsulinemic and insulin resistant (J. Clin. Invest., (1990) 85 : 962-967), whereas heterozygous are lean and normoglycemic. In db/db model, mouse progressively develops insulinopenia with age, a feature commonly observed in late stages of human type II diabetes when blood sugar levels are insufficiently controlled. The state of pancreas and its course vary according to the models. Since this model resembles that of type II diabetes mellitus, the compounds of the present invention were tested for blood sugar and triglycerides lowering activities.
Male C57BL/KsJ-db/db mice of 8 to 14 weeks age, having body weight range of 35 to 60 grams, bred at Dr. Reddy's Research Foundation (DRF) animal house, were used in the experiment. The mice were provided with standard feed (National Institute of Nutrition (NTN), Hyderabad, India) and acidified water, ad libitum. The. animals having more than 350 mg / dl blood sugar were used for testing. The number of animals in each group was 4.
Test compounds were suspended on 0.25 % carboxymethyl cellulose and administered to test group at a dose of 0.1 mg to 30 mg / kg through oral gavage daily for 6 days. The control group received vehicle (dose 10 ml / kg). On 6th day the blood samples were collected one hour after administration of test compounds / vehicle for assessing the biological activity. The random blood sugar and triglyceride levels were measured by collecting blood (100 μl) through orbital sinus, using heparinised capillary in tubes containing EDTA which was centrifuged to obtain plasma. The plasma glucose and triglyceride levels were measured spectrometrically, by glucose oxidase and glycerol-3-PO4 oxidase/peroxidase enzyme (Dr. Reddy's Lab. Diagnostic Division Kits, Hyderabad, India) methods respectively.
The blood sugar and triglycerides lowering activities of the test compound was calculated according to the formula.
Formulae for calculation :
Percent reduction in Blood sugar can be calculated according to the formula :
TT / OT
Percent reduction (%) = 1 - X 100
TC / OC
OC = Zero day control group value OT = Zero day treated group value TC = Test day control group value TT = Test day treated group value.

Claims

Claims :
1. A compound of formula (I)
Figure imgf000011_0001
wherein R represents hydroxy or a protecting group such as (CpC8)alkoxy- CH2-O-, mesylate, tosylate, triflate or halogen atom
2. A compound according to claim 1 which is selected from : (-) 2-Amino 3-[4-(2-chloroethoxy)phenyl]propanoic acid ; (-) 2-Amino 3-[4-(2-bromoethoxy)phenyl]propanoic acid ; (-) 2-Amino 3-[4-(2-methoxymethoxyethoxy)phenyl]propanoic acid ; (-) 2-Amino 3-[4-(2-ethoxymethoxyethoxy)phenyl]propanoic acid ; (-) 2-Amino 3-[4-[2-(4-methylphenyl sulfonyloxy)ethoxy]phenyl]propanoic aci ;
3. A process for the preparation of compounds of formula (I)
Figure imgf000011_0002
wherein R represents hydroxy or a protecting group such as (Cι-C8)alkoxy- CH2-0-, mesylate, tosylate, triflate or halogen atom, which comprises : i). protecting L-tyrosine of the formula (III)
Figure imgf000011_0003
with protecting groups such as copper acetate, acetone, benzaldehyde in the presence of a base to produce a compound of formula (IV)
Figure imgf000012_0001
where X represents a protecting group such as copper, acetonide, benzylidine and the like, ii). reacting the compound of formula (IV) with compound of formula (V)
R^Lι (V) where R is as defined above and L1 is a leaving group such as halogen, hydroxy, mesylate, tosylate and the like to produce a compound of formula (VI)
Figure imgf000012_0002
iii). deprotecting the compound of formula (VI) to yield pure compound of formula (I).
4. The process as defined in claim 3, wherein the protection in step (i) is carried out in the presence of alkaline solutions such as sodium carbonate, potassium carbonate, NaH, NaOMe or potassium tertiary butoxide.
5. The process as defined in claims 3 and 4, wherein the protection in step (i) is carried out at a temperature in the range of 40 C to 140 °C, for a period in the range of 2 h to 20 h.
6. The process as defined in claims 3 to 5, wherein the reaction in step (ii) is carried out in the presence of bases such as potassium carbonate or sodium carbonate.
7. The process as defined in claims 3 to 6, wherein the reaction in step (ii) is carried out in the presence of solvents such as toluene, xylene, DMF or DMA
8. The process as defined in claims 3 to 7, wherein the reaction in step (ii) is carried out at temperature in the range of 60 to 110 °C and the duration of the reaction may range from 2-40 h.
9. The process as defined in claims 3 to 8, wherein the deprotection in step (iii) is carried out in the presence of acids such as hydrochloric acid, sulfuric acid or acetic acid.
10. The process as defined in claims 3 to 9, wherein the deprotection in step (iii) is carried in the presence of solvents such as methanol, ethanol, propanol or isopropanol.
11. The process as defined in claims 3 to 10, wherein the deprotection in step (iii) is carried out at a temperature in the range of 60 to 110 °C and the duration of the reaction may range from 2-40 h.
12. An intermediate of formula (IV)
Figure imgf000013_0001
wherein X is a protecting group such as copper, acetonide, benzylidine and the like.
13. An intermediate of formula (VI)
Figure imgf000014_0001
wherein R represents hydroxy or a protecting group such as (C)-C8)alkoxy- CH2-0-, mesylate, tosylate, triflate or halogen atom; X is a protecting group such as copper, acetonide, benzylidine and the like.
PCT/IN2001/000126 2001-06-28 2001-06-28 3-aryl-alpha-amino propanoic acid derivatives and a process for their preparation WO2003002514A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2001/000126 WO2003002514A1 (en) 2001-06-28 2001-06-28 3-aryl-alpha-amino propanoic acid derivatives and a process for their preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2001/000126 WO2003002514A1 (en) 2001-06-28 2001-06-28 3-aryl-alpha-amino propanoic acid derivatives and a process for their preparation

Publications (1)

Publication Number Publication Date
WO2003002514A1 true WO2003002514A1 (en) 2003-01-09

Family

ID=11076363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2001/000126 WO2003002514A1 (en) 2001-06-28 2001-06-28 3-aryl-alpha-amino propanoic acid derivatives and a process for their preparation

Country Status (1)

Country Link
WO (1) WO2003002514A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01228946A (en) * 1988-03-09 1989-09-12 Suntory Ltd Synthesis of beta-hydroxyphenetylamines
WO1991001901A1 (en) * 1989-08-03 1991-02-21 Kress Corporation Elevatable dump box carrier with tilt frame and abuttable rear latch

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01228946A (en) * 1988-03-09 1989-09-12 Suntory Ltd Synthesis of beta-hydroxyphenetylamines
WO1991001901A1 (en) * 1989-08-03 1991-02-21 Kress Corporation Elevatable dump box carrier with tilt frame and abuttable rear latch

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANGEWANDTE CHEMIE. INTERNATIONAL EDITION., vol. 38, no. 10, 1999, VERLAG CHEMIE. WEINHEIM., DE, pages 1414 - 1416, XP001040312, ISSN: 0570-0833 *
CHEMICAL ABSTRACTS, vol. 130, no. 23, 7 June 1999, Columbus, Ohio, US; abstract no. 308497w, WESTER, HANS J., ET AL.: "Synthesis and radiopharmacology of O-(2-(18-F)-fluoroethyl)-L-tyrosine for tumor imaging." page 335; column 2; XP002188939 *
FRIEDRICH WEYGAND ET AL.: "2,2-Bis-trifluormethyl-oxazolidone-(5)", CHEMISCHE BERICHTE., vol. 99, no. 5, 1966, WEINHEIM DE, pages 1461 - 1469, XP002188937 *
J. NUCL. MED., vol. 40, no. 1, 1999, pages 205 - 212 *
PATENT ABSTRACTS OF JAPAN vol. 013, no. 553 (C - 663) 8 December 1989 (1989-12-08) *
THEODORA W. GREENE: "Protective groups in organic synthesis", 1999, JOHN WILEY & SONS, INC., XP002188938 *

Similar Documents

Publication Publication Date Title
US6130214A (en) Benzothiazin and benzoxazin derivatives; their preparation and uses
US7119198B2 (en) Tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
JP4427825B2 (en) Pharmaceutical composition having cholesterol lowering action
KR100293891B1 (en) Hannaphthalene derivatives
US20080221159A1 (en) Inhibitors of human immunodeficiency virus replication
KR20080098615A (en) Compounds for the treatment of metabolic disorders
EA014720B1 (en) Compounds and methods for modulating fxr
JP2002507543A (en) Bicyclic compound, method for producing the same, and pharmaceutical composition containing them
KR20090010035A (en) Compounds for the treatment of metabolic disorders
JP2001515490A (en) LTA lower 4 hydrolase inhibitor
US20240109895A1 (en) Oxaspiro substituted pyrrolopyrazole derivative, intermediate thereof, and preparation method therefor
EP0140359B1 (en) Morpholine derivatives
WO2003002514A1 (en) 3-aryl-alpha-amino propanoic acid derivatives and a process for their preparation
US5889032A (en) Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US20040248849A1 (en) 3-Aryl-A-oxy substituted propanoic acids and a process for their preparation
US6265401B1 (en) Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
NO860458L (en) ANTIHYPERTENSIVE DIHYDROPYRIDINE DERIVATIVES.
US5051438A (en) Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof, compositions and use
RU2247722C2 (en) Derivatives of aryl carboxylic acids, methods for their preparing, pharmaceutical composition based on thereof, methods for treatment and prophylaxis of different diseases, intermediate compounds and methods for their preparing
NO309649B1 (en) <alpha> - (substituted alkylphenyl) -4- (hydroxydiphenylmethyl) -1-piperidinebutanol derivatives and their use in the preparation of antihistamines, anti-allergy agents and bronchodilators
WO2003010157A1 (en) Dioxane derivatives and a process for their preparation
EP1036075B1 (en) Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypolipidemia and antihypertensive properties
WO2003008362A1 (en) Novel 3-aryl-2-hydroxy propanol derivatives and a process for their preparation
WO2003002508A1 (en) Derivatives of para-ethoxy-phenillactic acid
HUE030901T2 (en) Acrylamide compounds as histamine h3 receptor ligands

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG US

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP